These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
668 related articles for article (PubMed ID: 25316870)
21. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. Thompson KM; Duintjer Tebbens RJ BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234 [TBL] [Abstract][Full Text] [Related]
22. A vision of a world without polio: the OPV cessation strategy. Heymann DL; Sutter RW; Aylward RB Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224 [TBL] [Abstract][Full Text] [Related]
23. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071 [TBL] [Abstract][Full Text] [Related]
24. Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria. Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM PLoS One; 2015; 10(6):e0130123. PubMed ID: 26068928 [TBL] [Abstract][Full Text] [Related]
25. Anomalous observations on IPV and OPV vaccination. John TJ Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328 [TBL] [Abstract][Full Text] [Related]
26. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D; MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675 [TBL] [Abstract][Full Text] [Related]
27. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Duintjer Tebbens RJ; Pallansch MA; Kim JH; Burns CC; Kew OM; Oberste MS; Diop OM; Wassilak SG; Cochi SL; Thompson KM Risk Anal; 2013 Apr; 33(4):680-702. PubMed ID: 23470192 [TBL] [Abstract][Full Text] [Related]
28. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Thompson KM; Tebbens RJ Expert Rev Vaccines; 2012 Apr; 11(4):449-59. PubMed ID: 22551030 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan. Duintjer Tebbens RJ; Thompson KM Risk Anal; 2019 Feb; 39(2):389-401. PubMed ID: 30239026 [TBL] [Abstract][Full Text] [Related]
30. Cost analysis of post-polio certification immunization policies. Sangrujee N; Cáceres VM; Cochi SL Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295 [TBL] [Abstract][Full Text] [Related]
31. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263 [TBL] [Abstract][Full Text] [Related]
32. Circulating vaccine derived polio viruses and their impact on global polio eradication. Wagner BG; Earn DJ Bull Math Biol; 2008 Jan; 70(1):253-80. PubMed ID: 17934778 [TBL] [Abstract][Full Text] [Related]
37. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Thompson KM; Duintjer Tebbens RJ Medscape J Med; 2008; 10(8):190. PubMed ID: 18924642 [TBL] [Abstract][Full Text] [Related]
38. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638 [TBL] [Abstract][Full Text] [Related]
39. Polio endgame: the global introduction of inactivated polio vaccine. Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843 [TBL] [Abstract][Full Text] [Related]